Cost-effectiveness of maintenance niraparib with an individualized starting dosage in patients with platinum-sensitive recurrent ovarian cancer in China

Cost-effectiveness of maintenance niraparib with an individualized starting dosage in patients with platinum-sensitive recurrent ovarian cancer in China

Objective: Niraparib improved survival in platinum-sensitive recurrent ovarian cancer (PSROC) patients versus routine surveillance, accompanied by increased costs. Based on the NORA trial, we evaluated for the first time the cost-effectiveness of maintenance niraparib with individualized starting do...

Full description

Bibliographic Details
Main Authors: Yin Shi, Di Xiao, Shuishi Li, Shao Liu, Yu Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-07-01
Series:Frontiers in Pharmacology
Subjects:
niraparib
routine surveillance
ovarian cancer
maintenance therapy
cost-effectiveness
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1198585/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1198585/full

Similar Items